Literature DB >> 17639883

Efficacy of nonviral gene transfer in the canine brain.

Seunguk Oh1, G Elizabeth Pluhar, Elizabeth A McNeil, Kurt M Kroeger, Chunyan Liu, Maria G Castro, Pedro R Lowenstein, Andrew Freese, John R Ohlfest.   

Abstract

OBJECT: The purpose of this study was to evaluate the gene transfer capability and tolerability of plasmid DNA/polyethylenimine (PEI) complexes in comparison with adenovirus and naked plasmid DNA in the canine brain.
METHODS: Plasmid or adenoviral vectors encoding firefly luciferase were injected directly into the cerebral parenchyma of five adult dogs at varying doses and volumes. Serial physical and neurological examinations, as well as blood and cerebrospinal fluid (CSF) analyses, were conducted before and after the surgery for 3 days. Three days after gene delivery, a luciferase activity assay and immunofluorescence analysis were used to test the brain tissue for gene expression.
RESULTS: Injection into the brain parenchyma resulted in gene transfer throughout the cerebrum with every vector tested. Luciferase expression was highest when adenovirus vectors were used. Injection of plasmid DNA/PEI complexes and naked DNA resulted in similar levels of luciferase expression, which were on average 0.5 to 1.5% of the expression achieved with adenovirus vectors. Immunofluorescent microscopy analysis revealed that plasmid DNA/PEI complexes transduced mainly neurons, whereas adenovirus transduced mainly astrocytes. No significant acute side effects or neurological complications were observed in any of the dogs. Mononuclear cell counts significantly increased in the CSF after adenovirus injection and modestly increased after injection of plasmid DNA/PEI complexes, suggesting that a mild, acute inflammatory response occurred in the central nervous system (CNS).
CONCLUSIONS: Compared with rodent models that are limited by very small brains, the dog is an excellent preclinical model in which to assess the distribution and safety of emerging gene transfer technologies. In this study, short-term gene transfer was evaluated as a prelude to long-term expression and safety studies. The authors conclude that the viral and nonviral vectors tested were well tolerated and effective at mediating gene transfer throughout a large portion of the canine brain. The nonviral plasmid vectors were less effective than adenovirus, yet they still achieved appreciable gene expression levels. Due to reduced gene transfer efficiency relative to viral vectors, nonviral vectors may be most useful when the expressed protein is secreted or exerts a bystander effect. Nonviral vectors offer an alternative means to genetically modify cells within the CNS of large mammals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17639883      PMCID: PMC2384235          DOI: 10.3171/JNS-07/07/0136

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  51 in total

Review 1.  Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective.

Authors:  Pedro R Lowenstein
Journal:  Trends Immunol       Date:  2002-01       Impact factor: 16.687

Review 2.  Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences.

Authors:  P R Lowenstein; M G Castro
Journal:  Gene Ther       Date:  2003-06       Impact factor: 5.250

3.  Virology and immunology of gene therapy, or virology and immunology of high MOI infection with defective viruses.

Authors:  P R Lowenstein
Journal:  Gene Ther       Date:  2003-06       Impact factor: 5.250

4.  Progress and challenges in viral vector-mediated gene transfer to the brain.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Curr Opin Mol Ther       Date:  2002-08

Review 5.  Critical issues in gene therapy for neurologic disease.

Authors:  Gary Hsich; Miguel Sena-Esteves; Xandra O Breakefield
Journal:  Hum Gene Ther       Date:  2002-03-20       Impact factor: 5.695

6.  Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain.

Authors:  C E Thomas; D Birkett; I Anozie; M G Castro; P R Lowenstein
Journal:  Mol Ther       Date:  2001-01       Impact factor: 11.454

7.  Dynamics of transgene expression in human glioblastoma cells mediated by herpes simplex virus/adeno-associated virus amplicon vectors.

Authors:  Paula Lam; Kam M Hui; Yaming Wang; Paul D Allen; David N Louis; C J Yuan; Xandra O Breakefield
Journal:  Hum Gene Ther       Date:  2002-12-10       Impact factor: 5.695

8.  Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer.

Authors:  Malgorzata Kursa; Greg F Walker; Vanessa Roessler; Manfred Ogris; Wolfgang Roedl; Ralf Kircheis; Ernst Wagner
Journal:  Bioconjug Chem       Date:  2003 Jan-Feb       Impact factor: 4.774

9.  IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13.

Authors:  Akiva Mintz; Denise M Gibo; Becky Slagle-Webb; Neil D Christensen; Waldemar Debinski
Journal:  Neoplasia       Date:  2002 Sep-Oct       Impact factor: 5.715

10.  Preferential transfection of adult mouse neural stem cells and their immediate progeny in vivo with polyethylenimine.

Authors:  Gregory F Lemkine; Stefano Mantero; Carole Migné; Aicha Raji; Daniel Goula; Priscilla Normandie; Giovanni Levi; Barbara A Demeneix
Journal:  Mol Cell Neurosci       Date:  2002-02       Impact factor: 4.314

View more
  13 in total

Review 1.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

Review 2.  Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.

Authors:  Michael R Olin; G Elizabeth Pluhar; Brian M Andersen; Rob Shaver; Nate N Waldron; Christopher L Moertel
Journal:  Crit Rev Immunol       Date:  2014       Impact factor: 2.214

3.  Biodegradable DNA Nanoparticles that Provide Widespread Gene Delivery in the Brain.

Authors:  Panagiotis Mastorakos; Eric Song; Clark Zhang; Sneha Berry; Hee Won Park; Young Eun Kim; Jong Sung Park; Seulki Lee; Jung Soo Suk; Justin Hanes
Journal:  Small       Date:  2015-12-17       Impact factor: 13.281

4.  Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.

Authors:  Weidong Xiong; Marianela Candolfi; Chunyan Liu; A K M Ghulam Muhammad; Kader Yagiz; Mariana Puntel; Peter F Moore; Julie Avalos; John D Young; Dorothy Khan; Randy Donelson; G Elizabeth Pluhar; John R Ohlfest; Kolja Wawrowsky; Pedro R Lowenstein; Maria G Castro
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

Review 5.  Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.

Authors:  Marianela Candolfi; Kurt M Kroeger; A K M G Muhammad; Kader Yagiz; Catherine Farrokhi; Robert N Pechnick; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

6.  Long-term transgene expression in the central nervous system using DNA nanoparticles.

Authors:  David M Yurek; Anita M Fletcher; George M Smith; Kim B Seroogy; Assem G Ziady; Joseph Molter; Tomasz H Kowalczyk; Linas Padegimas; Mark J Cooper
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

7.  Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons.

Authors:  David M Yurek; Anita M Flectcher; Tomasz H Kowalczyk; Linas Padegimas; Mark J Cooper
Journal:  Cell Transplant       Date:  2009-06-22       Impact factor: 4.064

8.  Whole animal in vivo imaging after transient, nonviral gene delivery to the rat central nervous system.

Authors:  Ellen S Hauck; Shaomin Zou; Keith Scarfo; Michael H Nantz; James G Hecker
Journal:  Mol Ther       Date:  2008-08-26       Impact factor: 11.454

Review 9.  Gene delivery with viral vectors for cerebrovascular diseases.

Authors:  Yu Gan; Zheng Jing; Ruth Anne Stetler; Guodong Cao
Journal:  Front Biosci (Elite Ed)       Date:  2013-01-01

10.  Mitogen activated protein kinase phosphatase-1 prevents the development of tactile sensitivity in a rodent model of neuropathic pain.

Authors:  Christian Ndong; Russell P Landry; Joyce A DeLeo; Edgar Alfonso Romero-Sandoval
Journal:  Mol Pain       Date:  2012-04-27       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.